{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:11:26Z","timestamp":1792591886547,"version":"4.5.0"},"reference-count":34,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.3201\/eid3003.230893","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T21:15:55Z","timestamp":1706735755000},"source":"Crossref","is-referenced-by-count":15,"title":["Population-Based Evaluation of Vaccine Effectiveness against SARS-CoV-2 Infection, Severe Illness, and Death, Taiwan"],"prefix":"10.3201","volume":"30","author":[{"given":"Cheng-Yi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Wei","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Lun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Hsiang","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jih-Haw","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3003.230893-202401311601-R1","doi-asserted-by":"publisher","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"key-10.3201\/eid3003.230893-202401311601-R2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3003.230893-202401311601-R3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1473-3099(22)00141-4","article-title":"Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.","volume":"22","author":"Sheikh","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3003.230893-202401311601-R4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12879-022-07814-4","article-title":"High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron.","volume":"22","author":"Baum","year":"2022","journal-title":"BMC Infect Dis"},{"key":"key-10.3201\/eid3003.230893-202401311601-R5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.15585\/mmwr.mm7104e3","article-title":"Effectiveness of a third dose of mRNA vaccines against COVID-19\u2013associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance\u2014VISION Network, 10 States, August 2021\u2013January 2022.","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.3201\/eid3003.230893-202401311601-R6","doi-asserted-by":"publisher","first-page":"E143","DOI":"10.1503\/cmaj.221068","article-title":"Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19-related deaths among people with multimorbidity: a cohort study.","volume":"195","author":"Lai","year":"2023","journal-title":"CMAJ"},{"key":"key-10.3201\/eid3003.230893-202401311601-R7","doi-asserted-by":"publisher","first-page":"e072065","DOI":"10.1136\/bmj-2022-072065","article-title":"Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.","volume":"379","author":"Adams","year":"2022","journal-title":"BMJ"},{"key":"key-10.3201\/eid3003.230893-202401311601-R8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3201\/eid2906.230130","article-title":"SARS-CoV-2 vaccine effectiveness against Omicron variant in infection-naive population, Australia, 2022.","volume":"29","author":"Bloomfield","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid3003.230893-202401311601-R9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1473-3099(22)00732-0","article-title":"Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.","volume":"23","author":"Tsang","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3003.230893-202401311601-R10","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1016\/j.vaccine.2022.08.045","article-title":"Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection.","volume":"40","author":"Vietri","year":"2022","journal-title":"Vaccine"},{"key":"key-10.3201\/eid3003.230893-202401311601-R11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.24875\/RIC.22000159","article-title":"Significant rise in SARS-CoV-2 reinfection rate in vaccinated hospital workers during the Omicron wave: a prospective cohort study.","volume":"74","author":"Ochoa-Hein","year":"2022","journal-title":"Rev Invest Clin"},{"key":"key-10.3201\/eid3003.230893-202401311601-R12","doi-asserted-by":"publisher","first-page":"100572","DOI":"10.1016\/j.lanwpc.2022.100572","article-title":"SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period.","volume":"26","author":"Yang","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"key-10.3201\/eid3003.230893-202401311601-R13","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41467-022-30884-6","article-title":"Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine.","volume":"13","author":"Patalon","year":"2022","journal-title":"Nat Commun"},{"key":"key-10.3201\/eid3003.230893-202401311601-R14","unstructured":"UK Health Security Agency. COVID-19 vaccine surveillance report Week 40. London: Public Health England, UK Health Security Agency; 2022."},{"key":"key-10.3201\/eid3003.230893-202401311601-R15","unstructured":"Ontario Agency for Health Protection and Promotion (Public Health Ontario). Confirmed cases of COVID-19 following vaccination in Ontario: December 14, 2020 to April 23, 2023. Toronto (ON): King\u2019s Printer for Ontario; 2023."},{"key":"key-10.3201\/eid3003.230893-202401311601-R16","unstructured":"Public Health Agency of Sweden. Protection by a third and fourth dose of vaccine against COVID-19 among persons aged 65 years and older: based on Swedish data from February to August 2022. \u00d6stersund (Sweden): The Agency; 2022."},{"key":"key-10.3201\/eid3003.230893-202401311601-R17","unstructured":"Taiwan Centers for Disease Control. CECC raises epidemic warning to Level 3 nationwide from May 19 to May 28; strengthened measures and restrictions introduced across Taiwan to reduce community transmission [in Taiwanese] [cited 2023 Jun 8]. https:\/\/www.cdc.gov.tw\/En\/Bulletin\/Detail\/VN_6yeoBTKhRKoSy2d0hJQ"},{"key":"key-10.3201\/eid3003.230893-202401311601-R18","unstructured":"Taiwan Centers for Disease Control. CECC extends nationwide Level 3 epidemic alert until July 26 to safeguard disease prevention efforts in the community; CECC to partially relax restrictions starting July 13 [in Taiwanese] [cited 2023 Jun 8]. https:\/\/www.cdc.gov.tw\/En\/Bulletin\/Detail\/vlmAORqyqEntz1Tr_Ls7DQ"},{"key":"key-10.3201\/eid3003.230893-202401311601-R19","unstructured":"Taiwan Centers for Disease Control. Taiwan to start COVID-19 vaccination with AstraZeneca vaccine on March 22 [in Taiwanese] [cited 2023 Jun 8]. https:\/\/www.cdc.gov.tw\/Category\/ListContent\/EmXemht4IT-IRAPrAnyG9A"},{"key":"key-10.3201\/eid3003.230893-202401311601-R20","unstructured":"de Guzman C. Taiwan is abandoning its zero-COVID strategy in favor of a \u2018new model\u2019 of coronavirus containment. Time. 2022 May 12 [cited 2023 Apr 6]. https:\/\/time.com\/6174132\/taiwan-covid-strategy"},{"key":"key-10.3201\/eid3003.230893-202401311601-R21","unstructured":"Taiwan Centers for Disease Control. Community variants and genomic surveillance for SARS-CoV-2 in Taiwan [in Taiwanese]. Center for Diagnostic and Vaccine Development, editor. Taipei: The Centers; 2022 [cited 2023 Jun 8]. https:\/\/www.cdc.gov.tw\/Bulletin\/Detail\/CvcKJh_3GBr7CpYQHY8TEA"},{"key":"key-10.3201\/eid3003.230893-202401311601-R22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1473-3099(22)00732-0","article-title":"Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.","volume":"23","author":"Tsang","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3003.230893-202401311601-R23","unstructured":"Centers for Disease Control and Prevention. Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity. Atlanta: The Centers; 2020."},{"key":"key-10.3201\/eid3003.230893-202401311601-R24","doi-asserted-by":"publisher","first-page":"e944","DOI":"10.1016\/S2666-5247(22)00287-7","article-title":"Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.","volume":"3","author":"Chemaitelly","year":"2022","journal-title":"Lancet Microbe"},{"key":"key-10.3201\/eid3003.230893-202401311601-R25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/22221751.2022.2046446","article-title":"The protection of naturally acquired antibodies against subsequent SARS-CoV-2 infection: a systematic review and meta-analysis.","volume":"11","author":"Chen","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"key-10.3201\/eid3003.230893-202401311601-R26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.vaccine.2022.10.030","article-title":"An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.","volume":"41","author":"Torales","year":"2023","journal-title":"Vaccine"},{"key":"key-10.3201\/eid3003.230893-202401311601-R27","doi-asserted-by":"publisher","first-page":"e2336854","DOI":"10.1001\/jamanetworkopen.2023.36854","article-title":"Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry. Estimated effectiveness of a primary cycle of protein recombinant vaccine NVX-CoV2373 against COVID-19.","volume":"6","author":"Mateo-Urdiales","year":"2023","journal-title":"JAMA Netw Open"},{"key":"key-10.3201\/eid3003.230893-202401311601-R28","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3003.230893-202401311601-R29","doi-asserted-by":"publisher","first-page":"100465","DOI":"10.1016\/j.lana.2023.100465","article-title":"The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study.","volume":"20","author":"Santos","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"key-10.3201\/eid3003.230893-202401311601-R30","unstructured":"World Health Organization. SAGE updates COVID-19 vaccination guidance [cited 2023 Jun 8]. https:\/\/www.who.int\/news\/item\/28-03-2023-sage-updates-covid-19-vaccination-guidance"},{"key":"key-10.3201\/eid3003.230893-202401311601-R31","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/22221751.2022.2072773","article-title":"Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.","volume":"11","author":"Suah","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"key-10.3201\/eid3003.230893-202401311601-R32","doi-asserted-by":"publisher","first-page":"100626","DOI":"10.1016\/j.lana.2023.100626","article-title":"Effectiveness of COVID-19 vaccines against hospitalisation in Latin America during three pandemic waves, 2021-2022: a test-negative case-control design.","volume":"27","author":"Nogareda","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"key-10.3201\/eid3003.230893-202401311601-R33","unstructured":"Taiwan Central News Agency. A total of ten countries recognized the COVID-19 vaccine effectiveness of Medigen: Taiwan\u2019s Deputy Minister [in Taiwanese] [cited 2023 Jun 8]. https:\/\/www.cna.com.tw\/news\/ahel\/202210200215.aspx"},{"key":"key-10.3201\/eid3003.230893-202401311601-R34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/cid\/ciac803","article-title":"Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial.","volume":"76","author":"Heath","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/3\/23-0893_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T18:37:25Z","timestamp":1732905445000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/30\/3\/23-0893_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3003.230893","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}